Director Dealing | 08-Aug-2025 | 12:31 | RNS |
Director/PDMR Shareholding | 04-Aug-2025 | 10:23 | RNS |
Strong Phase 2 data on iSCIB1+ in Melanoma | 22-Jul-2025 | 07:00 | RNS |
Share Option Exercise | 16-Jul-2025 | 07:00 | RNS |
Scancell initiates new arm in SCOPE Phase 2 study | 25-Jun-2025 | 07:00 | RNS |
Director Dealing | 21-May-2025 | 07:00 | RNS |
Partnership with NHS Cancer Vaccine Launch Pad | 14-Apr-2025 | 07:00 | RNS |
Scancell to present at 2025 AACR Annual Meeting | 01-Apr-2025 | 07:00 | RNS |
Issue of share options | 20-Feb-2025 | 07:00 | RNS |
Scancell presenting at AACR IO conference | 17-Feb-2025 | 07:00 | RNS |
Interim Results | 30-Jan-2025 | 07:00 | RNS |
Notice of Interim Results | 23-Jan-2025 | 07:00 | RNS |
Modi-1 Vaccine Achieves Early Clinical Validation | 09-Jan-2025 | 07:00 | RNS |
Result of Retail Offer and Total Voting Rights | 09-Dec-2024 | 11:41 | RNS |
Result of Placing and Subscription | 05-Dec-2024 | 12:39 | RNS |
Currency | UK Pounds |
Share Price | 10.50p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 17.50 |
52 Week Low | 7.50 |
Volume | 369,114 |
Shares Issued | 1,037.78m |
Market Cap | £108.97m |
Value | ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
Strong Buy | 1 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
15:22 | 250,000 @ 10.90p |
15:34 | 14,365 @ 10.40p |
15:21 | 4,565 @ 10.15p |
14:50 | 50,000 @ 10.60p |
13:14 | 50,184 @ 10.30p |
CFO | Sath Nirmalananthan |
CEO | Phil L'Huillier |
You are here: research